An interventional study of Sphenopalatine Ganglion Block and Dexmedetomidine in Sphenopalatine Ganglion Nerve Block and Transnasal Endoscopic Pitutary Surgery, sponsored by Zagazig University. Active, not recruiting at 1 site in Egypt. Open to participants aged 21 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Zagazig University · Not applicable, Interventional, and Health services research
Improving pain and surgical field by using sphenopalatine ganglion block and dexmedetomidine in trans-nasal endoscopic pituitary surgery.
Pituitary neoplasm is one of the most common sellar pathology. Trans-nasal endoscopic pituitary surgery (TEPS) evolved rapidly, almost replacing the craniotomy approach. TEPS, a surgical instrument, is primarily executed through a minimally invasive approach through the nostril to access a pituitary tumor.
That is why the anesthetic plan must ensure the best possible surgical field visualization and the most adequate analgesia.
Multimodal anesthesia including regional and general anesthesia are obtained to optimize surgical field by decreasing bleeding, reduce pain, promote rapid recovery and potential economic gains for the hospital.
The sphenopalatine ganglion block (SPGB) is considered one of the regional anesthetic techniques that is safe and easy anesthetic procedure used to control bleeding and for postoperative analgesia.
Dexmedetomidine (DEX) has become popular for induced hypotension. It is an α2-adrenoceptor agonist with a sympatholytic and analgesic effect. It provides a unique conscious sedation without respiratory depression. It is used effectively in optimizing surgical field through its hemodynamic stability effect.
Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: General Anesthesia (control group)
Procedure: Sphenopalatine Ganglion Block
Drug: Dexmedetomidine
patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
patients will be operated under general anesthesia including routine protocol for these cases
Postoperative pain using VAS scale.
Pain will be assessed based on VAS scale from (1-10), as 1 is the least pain and 10 is the maximal pain possible at 2, 4, 6, 12 and 24h after surgery.
Time frame: 24hours
Surgical field using Average Category Scale (ACS).
Done by asking the surgeon about amount of bleeding on a scale of (0-5) as 0= no bleeding and 5= sever bleeding, every 15 min interval till the end of surgery.
Time frame: 5hours
Plan to share: Undecided
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zagazig University